Skip to main content

Table 2 Clinical information of glioma patients in the training and testing sets

From: Development and validation of a two glycolysis-related LncRNAs prognostic signature for glioma and in vitro analyses

 

Training sets

p

Testing sets

p

Total

(N = 417)

Expression

Total

(N = 172)

Expression

High

(N = 203)

Low

(N = 214)

High

(N = 88)

Low

(N = 84)

Gender

   

0.832

   

0.687

 Female

184

(44.1%)

88

(43.3%)

96

(44.9%)

 

68

(39.5%)

33

(37.5%)

35

(41.7%)

 

 Male

233

(55.9%)

115

(56.7%)

118

(55.1%)

104

(60.5%)

55

(62.5%)

49

(58.3%)

 

Age (years)

   

 < 0.001

   

 < 0.001

  ≥ 60

93

(22.3%)

74

(36.5%)

19

(8.9%)

 

42

(24.4%)

37

(42.0%)

5

(6.0%)

 

  < 60

324

(77.7%)

129

(63.5%)

195

(91.1%)

130

(75.6%)

51

(58.0%)

79

(94.0%)

 

Cluster

   

 < 0.001

   

 < 0.001

 1

86

(20.6%)

82

(40.4%)

4

(1.9%)

 

36

(20.9%)

34

(38.6%)

2

(2.4%)

 

 2

331

(79.4%)

121

(59.6%)

210

(98.1%)

136

(79.1%)

54

(61.4%)

82

(97.6%)

 

Type

   

 < 0.001

   

0.604

 No PRT

85

(20.4%)

27

(13.3%)

58

(27.1%)

 

37

(21.5%)

16

(18.2%)

21

(25.0%)

 

 RT

52

(12.5%)

14

(6.9%)

38

(17.8%)

22

(12.8%)

12

(13.6%)

10

(11.9%)

 

 PT

38

(9.1%)

6

(3.0%)

32

(15.0%)

16

(9.3%)

7

(8.0%)

9

(10.7%)

 

 PT + RT

242

(58.0%)

156

(76.8%)

86

(40.2%)

97

(56.4%)

53

(60.2%)

44

(52. 4%)

 

IDH

   

 < 0.001

   

 < 0.001

 IDHmut-codel

114

(27.3%)

21

(10.3%)

93

(43.5%)

 

38

(22.1%)

7

(8.0%)

31

(36.9%)

 

 IDHmut-non-codel

158

(37.9%)

43

(21.2%)

115

(53.7%)

 

68

(39.5%)

16

(18.2%)

52

(61.9%)

 

 IDHwt

139

(33.3%)

134

(66.0%)

5

(2.3%)

 

63

(36.6%)

63

(71.6%)

0

(0%)

 

 Missing

6

(1.4%)

5

(2.5%)

1

(0.5%)

 

3

(1.7%)

2

(2.3%)

1

(1.2%)

 

MGMT

   

 < 0.001

   

0.001

  + 

300

(71.9%)

101

(49.8%)

199

(93.0%)

 

123

(71.5%)

46

(52.3%)

77

(91.7%)

 

 –

96

(23.0%)

81

(39.9%)

15

(7.0%)

 

40

(23.3%)

33

(37.5%)

7

(8.3%)

 

 Missing

21

(5.0%)

21

(10.3%)

0

(0%)

 

9

(5.2%)

9

(10.2%)

0

(0%)

 

Grade

   

 < 0.001

   

 < 0.001

 G2

136

(32.6%)

25

(12.3%)

111

(51.9%)

 

55

(32.0%)

16

(18.2%)

39

(46.4%)

 

 G3

148

(35.5%)

75

(36.9%)

73

(34.1%)

 

64

(37.2%)

29

(33.0%)

35

(41.7%)

 

 G4

92

(22.1%)

92

(45.3%)

0

(0%)

 

41

(23.8%)

39

(44.3%)

2

(2.4%)

 

 Missing

41

(9.8%)

11

(5.4%)

30

(14.0%)

 

12

(7%)

4

(4.5%)

8

(9.5%)

 
  1. no PRT no Pharmacotherapy and radiotherapy; PT Pharmacotherapy; RT radiotherapy; + methylated, − unmethylated
Back to article page

Cell Division

ISSN: 1747-1028

Contact us